Volatile Organic Compounds (VOC) and Serum Leukotriene B4 between COPD Patients and COPD with Lung Cancer Patients
Downloads
Introduction: Chronic obstructive pulmonary disease (COPD) is estimated to become the third leading cause of death worldwide in 2030. COPD can affect the lungs and cause chronic systemic inflammation. Leukotriene B4 (LTB4) is involved in COPD and lung cancer pathogenesis. There has been the development of non-invasive methods for detecting lung disease in the last few decades, such as the examination of volatile organic compounds (VOC). This study aimed to analyze the serum LTB4 and the difference of VOCs in exhaled breath of stable COPD patients and COPD with lung cancer patients.
Methods: This case-control study recruited 20 stable COPD patients and 20 patients with COPD and lung cancer. An exhaled breath sample was collected in Tedlar bags and analyzed using an arrayed sensor breath analyzer to check the concentration of VOCs. Meanwhile, a venous blood sample was collected to examine the level of LTB4 using an ELISA kit. Independent t-test and Mann-Whitney test were used to analyze the data.
Results: The carbon dioxide (CO2), nitrogen dioxide (NO2), carbon monoxide (CO), benzene (C6H6), and propane (C3H8) levels were significantly different (p <0.05) in COPD-only patients compared to COPD with lung cancer patients. Serum LTB4 increased in both groups.
Conclusion: CO2, CO, and C3H8 levels increased, but the NO2 level decreased in COPD patients with lung cancer compared to COPD-only patients. Serum LTB4 increased in COPD with lung cancer patients.
Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. American Journal of Respiratory and Critical Care Medicine. 2017; 195(5): 557–582. https://doi.org/10.1164/rccm.201701-0218PP
Kaźmierczak M, Ciebiada M, PÄ™kala-Wojciechowska A, PawÅ‚owski M, Nielepkowicz-GoździÅ„ska A, Antczak A. Evaluation of Markers of Inflammation and Oxidative Stress in COPD Patients with or without Cardiovascular Comorbidities. Heart, Lung & Circulation. 2015; 24(8): 817–823. https://doi.org/10.1016/j.hlc.2015.01.019
Jareño-Esteban JJ, Muñoz-Lucas MÁ, Gómez-Martín í“, Utrilla-Trigo S, et al. Study of 5 Volatile Organic Compounds in Exhaled Breath in Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumologia. 2017; 53(5): 251–256. https://doi.org/10.1016/j.arbres.2016.09.003
Parris BA, Farrell HE, Fong KM, and Yang IA. Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. J Thorac Dis. 2019; 11(Suppl 17): S2155-S2172.
Besa V, Teschler H, Kurth I, Khan AM, Zarogoulidis P, Baumbach JI, et al. Exhaled Volatile Organic Compounds Discriminate Patients with Chronic Obstructive Pulmonary Disease from Healthy Subjects. International Journal of Chronic Obstructive Pulmonary Disease. 2015; 10: 399–406. https://doi.org/10.2147/COPD.S76212
Mansurova M, Ebert BE, Blank LM, Ibáñez AJ. A Breath Of Information: The Volatilome”. Current Genetics. 2018; 64(4): 959–964. https://doi.org/10.1007/s00294-017-0800-x
van de Kant KDG, van der Sande LJTM, Jöbsis Q, van Schayck OCP, Dompeling E. Clinical Use of Exhaled Volatile Organic Compounds in Pulmonary Diseases: A Systematic Review. Respiratory Research. 2012; 13(1): 117. https://doi.org/10.1186/1465-9921-13-117
Kazeminasab S, Emamalizadeh B, Jouyban A, Shoja MM, Khoubnasabjafari M. Macromolecular Biomarkers of Chronic Obstructive Pulmonary Disease in Exhaled Breath Condensate. Biomarkers in Medicine. 2020; 14(11): 1047–1063. https://doi.org/10.2217/bmm-2020-0121
Ntritsos G, Franek J, Belbasis L, Christou MA, et al. Gender-Specific Estimates of COPD Prevalence: A Systematic Review and Meta-Analysis. International Journal of Chronic Obstructive Pulmonary Disease. 2018; 13: 1507–1514. https://doi.org/10.2147/COPD.S146390
Schabath MB, Cote ML. Cancer progress and priorities: lung cancer. Cancer Epidemiol Biomarkers Prev. 2019; 28(10): 1563-1579.
Brandsma CA, de Vries M, Costa R, Woldhuis RR, Königshoff M, Timens W. Lung Ageing and COPD: Is There a Role for Ageing in Abnormal Tissue Repair?. European Respiratory Review : An Official Journal of the European Respiratory Society. 2017; 26(146). https://doi.org/10.1183/16000617.0073-2017
Forder A, Zhuang R, Souza VGP, Brockley LJ, et al. Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer. International Journal of Molecular Sciences. 2023; 24(3). https://doi.org/10.3390/ijms24032859
Wang C, Zhou J, Wang J, Li S, Fukunaga A, Yodoi J, Tian H. Progress in the Mechanism and Targeted Drug Therapy for COPD. Signal Transduction and Targeted Therapy. 2020; 5(1): 248. https://doi.org/10.1038/s41392-020-00345-x
Jala VR, Bodduluri SR, Satpathy SR, et al. The yin and yang of leukotriene B4 mediated inflammation in cancer. Semin Immunol. 2017; 33: 58-64.
Dananjaya A., Setyawan UA, Djajalaksana S, Wardoyo AYP. Change in Exhaled Volatile Organic Compounds (VOC) Profile and Interleukin-17 Serum in Lung Cancer Patient. J Respir Indo. 2023; 43(1). https://doi.org/10.36497/jri.v43i1.316
Mathews AM, Wysham NG, Xie J, Qin X, Giovacchini CX, Ekström M, MacIntyre NR. Hypercapnia in Advanced Chronic Obstructive Pulmonary Disease: A Secondary Analysis of the National Emphysema Treatment Trial. Chronic Obstructive Pulmonary Diseases (Miami, Fla.). 2020; 7(4): 336–345. https://doi.org/10.15326/jcopdf.7.4.2020.0176
Andersen ZJ, Hvidberg M, Jensen SS, Ketzel M, et al. Chronic Obstructive Pulmonary Disease and Long-Term Exposure to Traffic-Related Air Pollution: A Cohort Study. American Journal of Respiratory and Critical Care Medicine. 2011; 183(4): 455–461. https://doi.org/10.1164/rccm.201006-0937OC
Ejazi MA, Shameem M, Bhargava R, Ahmad Z, et al. Correlation of Exhaled Carbon Monoxide Level with Disease Severity in Chronic Obstruction Pulmonary Disease. Lung India : Official Organ of Indian Chest Society. 2018; 35(5): 401–406. https://doi.org/10.4103/lungindia.lungindia_11_18
Allers M, Langejuergen J, Gaida A, Holz O, Schuchardt S, Hohlfeld JM, Zimmermann S. Measurement of Exhaled Volatile Organic Compounds from Patients with Chronic Obstructive Pulmonary Disease (COPD) Using Closed Gas Loop GC-IMS and GC-APCI-MS. Journal of Breath Research. 2016; 10(2). https://doi.org/10.1088/1752-7155/10/2/026004
Filipiak W, Ruzsanyi V, Mochalski P, Filipiak A, et al. Dependence of Exhaled Breath Composition on Exogenous Factors, Smoking Habits and Exposure To Air Pollutants. Journal of Breath Research. 2012; 6(3). https://doi.org/10.1088/1752-7155/6/3/036008
Gashimova E, Temerdashev A, Porkhanov V, et al. Investigation of different approaches for exhaled breath and tumor tissue analysisto identify lung cancer biomarkers. Heliyon 6. 2020; e04224: 1-13.
Rocco G, Pennazza G, Santonico M, et al. Breathprinting and Early Diagnosis of Lung Cancer. Journal of Thoracic Oncology. 2018; 13(7): 883-894
Dragonieri S, Annema JT, Schot R, et al. An electronic nose in the discrimination of patients with non-small cell lung cancer and COPD. Lung cancer. 2008; 64: 166-170.
Copyright (c) 2024 Susanthy Djajalaksana, Aditya Sri Listyoko, Kevin Wahyudy Prasetyo, Arinto Yudi Ponco Wardoyo
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.
JR (